MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.gastrohep.2011.04.001

Медицинская библиотека · Gastroenterologia y hepatologia · 2011

Adalimumab is effective in long-term real life clinical practice in both luminal and perianal Crohn's disease. The Madrid experience.

Fortea-Ormaechea José Ignacio, González-Lama Yago, Casis Begoña, Chaparro María, López Serrano Pilar, Van Domselaar Manuel, Bermejo Fernando, Pajares Ramón, Ponferrada Angel, Vera María Isabel, Martínez Montiel Pilar, Gisbert Javier P, Pérez-Calle José Luis, López San Román Antonio, Abreu Luis, Menchén Luis Alberto, Marín-Jiménez Ignacio

СтатьяМногоцентровое исследованиеПеревод пока не подготовлен

Аннотация

OBJECTIVE

To evaluate effectiveness and safety of adalimumab in CD patients of the Madrid area and identify predictors of response.

METHODS

Multicenter retrospective survey of all CD patients treated with adalimumab in 9 hospitals of the Madrid area (Spain). Univariate and multivariate analysis of predictors of response was performed.

RESULTS

174 patients included (50% males) with a median follow-up of 40 weeks. 30% had active perianal fistulizing disease at the beginning of the therapy with adalimumab. 59% had been previously treated with infliximab, being the lost of response (42.2%) the most frequent cause of withdrawal of the drug. 33% of patients needed dose escalation from every-other week to every week. The median time for this dose escalation was 33 weeks (range 2-120). The percentages of complete response at 4 weeks, 6 months and end of follow-up were 63, 70 and 63% in luminal disease and 49, 50 and 41% in perianal disease respectively. The prevalence of adverse events was 18% (most frequent was: 5 abscesses) causing the withdrawal of the drug in 21% of them.

CONCLUSIONS

Adalimumab is effective and safe for the management of CD, even in refractory cases to infliximab.

Для цитирования: Fortea-Ormaechea José Ignacio, González-Lama Yago, Casis Begoña, Chaparro María, López Serrano Pilar, Van Domselaar Manuel, Bermejo Fernando, Pajares Ramón, Ponferrada Angel, Vera María Isabel, Martínez Montiel Pilar, Gisbert Javier P, Pérez-Calle José Luis, López San Román Antonio, Abreu Luis, Menchén Luis Alberto, Marín-Jiménez Ignacio. Adalimumab is effective in long-term real life clinical practice in both luminal and perianal Crohn's disease. The Madrid experience.. Gastroenterologia y hepatologia. 2011. DOI: 10.1016/j.gastrohep.2011.04.001.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.